Kristina Masson - 14 Nov 2023 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
EVP - Business Operations, Director
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Issuer symbol
ACRV
Transactions as of
14 Nov 2023
Net transactions value
-$9,652
Form type
4
Filing time
16 Nov 2023, 19:42:52 UTC
Previous filing
16 Nov 2022
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability $9,652 -1,900 -0.59% $5.08 318,805 14 Nov 2023 Direct F1
holding ACRV Common Stock 2,658,673 14 Nov 2023 See footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2 These securities are held by President and CEO, Peter Blume-Jensen, who is also Dr. Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney